Opus Capital Group LLC Has $570,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Opus Capital Group LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 79.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,939 shares of the company’s stock after purchasing an additional 1,741 shares during the quarter. Opus Capital Group LLC’s holdings in Johnson & Johnson were worth $570,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of JNJ. Knuff & Co LLC lifted its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after purchasing an additional 64 shares during the last quarter. Vertex Planning Partners LLC lifted its holdings in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after purchasing an additional 65 shares during the last quarter. Freedom Day Solutions LLC lifted its holdings in Johnson & Johnson by 1.1% during the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after purchasing an additional 66 shares during the last quarter. Traphagen Investment Advisors LLC lifted its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock valued at $1,699,000 after purchasing an additional 67 shares during the last quarter. Finally, Corepath Wealth Partners LLC lifted its holdings in Johnson & Johnson by 3.7% during the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JNJ. Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.9 %

Shares of NYSE JNJ opened at $157.93 on Thursday. The stock has a market cap of $380.23 billion, a P/E ratio of 23.75, a P/E/G ratio of 2.50 and a beta of 0.52. The firm has a 50 day moving average price of $148.34 and a 200 day moving average price of $155.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.29 earnings per share. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.